Zacks Research Has Negative Estimate for ResMed Q4 Earnings

ResMed Inc. (NYSE:RMD - Free Report) - Equities research analysts at Zacks Research reduced their Q4 2025 earnings estimates for ResMed in a research note issued to investors on Wednesday, May 14th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.39 per share for the quarter, down from their prior forecast of $2.43. The consensus estimate for ResMed's current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed's Q3 2026 earnings at $2.50 EPS and Q3 2027 earnings at $2.73 EPS.

RMD has been the subject of a number of other research reports. Stifel Nicolaus reduced their target price on ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a report on Wednesday, March 5th. UBS Group cut their price target on shares of ResMed from $290.00 to $285.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Morgan Stanley started coverage on shares of ResMed in a report on Wednesday, March 19th. They set an "overweight" rating and a $280.00 price objective on the stock. KeyCorp set a $274.00 target price on shares of ResMed in a research report on Thursday, April 24th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $258.83.

ResMed Price Performance

RMD stock traded down $2.49 on Monday, reaching $245.65. 847,104 shares of the company's stock were exchanged, compared to its average volume of 1,023,116. The stock has a fifty day moving average of $226.57 and a 200-day moving average of $234.27. The firm has a market cap of $36.02 billion, a PE ratio of 29.00, a P/E/G ratio of 1.53 and a beta of 0.78. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. ResMed has a twelve month low of $179.42 and a twelve month high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.36 by $0.01. The company had revenue of $1.29 billion for the quarter, compared to analysts' expectations of $1.28 billion. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The firm's quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.13 EPS.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 12th. Shareholders of record on Thursday, May 8th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's dividend payout ratio (DPR) is presently 23.79%.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 8,009 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $229.20, for a total transaction of $1,835,662.80. Following the sale, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $104,394,182.40. This trade represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $242.25, for a total transaction of $484,500.00. Following the sale, the director now owns 71,218 shares of the company's stock, valued at approximately $17,252,560.50. This trade represents a 2.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 48,949 shares of company stock valued at $11,335,320. Corporate insiders own 0.71% of the company's stock.

Hedge Funds Weigh In On ResMed

Several institutional investors and hedge funds have recently modified their holdings of the company. Global X Japan Co. Ltd. raised its holdings in ResMed by 121.4% in the 1st quarter. Global X Japan Co. Ltd. now owns 124 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 68 shares during the last quarter. Colonial Trust Co SC grew its position in shares of ResMed by 6,250.0% in the fourth quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 125 shares during the period. Optiver Holding B.V. acquired a new position in ResMed in the fourth quarter valued at $33,000. Golden State Wealth Management LLC increased its stake in ResMed by 384.8% in the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider's stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock worth $38,000 after buying an additional 150 shares during the period. Hedge funds and other institutional investors own 54.98% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.